Exact Sciences becomes wholly owned Abbott subsidiary after acquisition
Published on 09/28/2026 at 22:25 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Abbott completed its acquisition of Exact Sciences on March 23, 2026, according to an Abbott release filed with the U.S. Securities and Exchange Commission. Exact Sciences became a wholly owned subsidiary of Abbott upon completion of the transaction. Abbott’s filing identified the transaction as complete.
Listing ends
Abbott said March 20, 2026, was the last day of trading for Exact Sciences shares on the Nasdaq Stock Market. The company’s shares therefore no longer trade as a separately listed Nasdaq security. The SEC-filed release provided the trading-date detail.
Products added to Abbott’s portfolio
The release said Abbott’s cancer diagnostics portfolio now includes Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott described the transaction as expanding its presence in cancer screening and personalized diagnostics. Abbott’s announcement listed the products and strategic rationale.
